Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Major study data to look out for from ASH 2020

John Gribben • 20 Nov 2020
ASH 2020
Acute Myeloid Leukemia Follicular Lymphoma Leukemia Lymphoma Multiple Myeloma Non-Hodgkin Lymphoma Antibodies CAR-T Tisagenlecleucel
APOLLO ELARA ZUMA-5

John Gribben, MD, DSc, FRCP, FRCPath, FMedSci, Barts Cancer Institute, London, UK shares key study data to lookout for at ASH 2020. Early trials for many novel agents in both acute myeloid leukemia (AML) and multiple myeloma will be presented. Of particular interest to Prof. Gribben is the upcoming results of trials in follicular lymphoma, such as bispecific antibodies and CD19 CAR-T cells. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from John Gribben

2:42
Investigating the treatment preferences of physicians in R/R follicular lymphoma
John Gribben • 9 Dec 2023
1:20
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
John Gribben • 9 Dec 2023
1:04
The future of CLL therapy
John Gribben • 9 Dec 2023
Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals